ARMD is the primary cause of irreversible blindness in the Western world. The etiology of this condition is largely unknown and is thought to involve interplay of a number of modifiable and nonmodifiable risk factors. As the underlying pathologic mechanisms of the degenerative retinal disorder are discovered, therapies targeted to the involved pathways are being developed. The management of neovascular ARMD is promising, given the availability of antiangiogenic therapies (both established and upcoming). Despite the therapeutic modalities available, ARMD continues to have a high incidence, and there is a great need for more efficacious, more potent, and safer therapies.
US Pharmacist. 2015;40(6):22-26. © 2015 Jobson Publishing